InflaRx plans two Phase 2 izicopan trials in ANCA-associated vasculitis in 2027, first data in 2028

InflaRx plans to begin two Phase 2 trials of izicopan in ANCA-associated vasculitis in 2027, with first data expected in 2028.

Detected & updated continuously · Source: Nebula